Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

Management to Make Two Presentations on the Topic of Drug Repurposing and

Indian Clinical Trial Strategy

MORRISTOWN, N.J., Aug. 16 /PRNewswire/ -- Vicus Therapeutics, Inc., an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, and Chief Scientific Officer, Frederic Young, Ph.D., will each present at the 234th American Chemical Society National Meeting on Sunday, August 19, 2007. The Meeting is being held at the Boston Convention & Exhibition Center in Boston, MA.

Dr. Young will present "Hypothesis-driven Drug Repurposing Based on a Novel Systems Biology Approach," including a discussion of Vicus' complexity theory-based drug repurposing approach in creating a pipeline of product candidates for the treatment of important unmet medical needs. The Company's approach can be applied to the discovery of product candidates for any indication, including cancer cachexia, a metabolic disorder, mucositis, a wound healing disorder, and cancer fatigue, a CNS disorder. The specific application of this method will be discussed in the context of the Company's lead compound, VT-122. Dr. Young's presentation is scheduled for 11:45 a.m.

Mr. Maki's presentation, entitled "Synergistic Advantages of Drug Repurposing and Clinical Trial Off-shoring in India", will include a discussion of the unique synergistic advantages of drug re-profiling and off- shoring, as well as an overview of the steps necessary to realize such advantages. Specifically, Mr. Maki will provide highlights from the Company's ongoing Phase 2 clinical trial of VT-122 for cancer cachexia, now being conducted in the U.S. and India. In addition, he will review recent changes by the Drug Controller General of India (DCGI, the Indian FDA-regulatory equivalent), Indian clinical research infrastructure, and the acceptance of Indian data by the U.S. Food & Drug Administration (FDA) that is currently driving the expl
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...HESTER, Minn., Nov. 26 ...rd are at significantly increased risk of developi... findings of a Mayo Clinic study published this m...merican Academy of Pediatrics. , , The retr...7 patients with strabismus (misaligned eyes) and c...
(Date:11/26/2008)...dy Expanded to 406 Subjects , , FRANKLIN, M...s Inc. (OTC Bulletin Board: PLCSF) announced today...Food and Drug Administration (FDA) for its U.S. pi...any,s RenalGuard System(TM) and associated therap...y (CIN). , , The FDA also approved PLC,s re...
(Date:11/25/2008)...ISVILLE, Ky., Nov. 25 K...urgeons performed the fifth U.S. hand transplant o... at Louisville,s Jewish Hospital Hand Care Center ...began around noon and was completed shortly after ... http://www.newscom.com/cgi-bin/prnh/20081125/DC4...
(Date:11/25/2008)...TH SAN FRANCISCO, Calif., Nov. 25 ...velopment of novel therapeutics that target,prote...iseases, today,announced that data from two ongoi...iple myeloma will be presented at the upcoming 50t...ology (ASH). Carfilzomib is the first in a new cl...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 1Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 2Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 3Rocker Joel Madden Named Newest UNICEF Goodwill Ambassador 23343 1Rocker Joel Madden Named Newest UNICEF Goodwill Ambassador 23343 2Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference 23340 1Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference 23340 2Physicians Practice Promotes Key Executives 23337 1Physicians Practice Promotes Key Executives 23337 2
...t Randomized, Placebo-controlled Trial,Ever Conduc...linical Oncology, CHICAGO, June 04, 2007 /PRNewswi...ed, placebo-controlled clinical trial ever,conduct...L) showed,that ONTAK was more than twice as effect... patients with CTCL. [Abstract number 8026],The pr...
...With Follicular Lymphoma Reported,Today at ASCO An...ire/ -- GlaxoSmithKline plc,announced today long-t...e one-week course of frontline treatment with the ...ine I-131 Tositumomab) in,76 patients with newly d...a (NHL). This regimen was found to induce durable ...
Other Medicine Technology:Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
(Date:12/2/2008)...orld Wide Dictation Service, one of the premier le...ption, and legal dictation transcription, has joi... non-profit organization geared to the betterment ...amilies throughout Lower Westchester County, New Y...) December 3, 2008 -- World Wide Dictation Service...
(Date:12/2/2008)...oes your over-the-phone interpretation vendor cont...completed the call? , Was...orld of over-the-phone interpretation (OPI), every...er one minute can add up over the course of a bill...ganization employs an over-the-phone interpretatio...
(Date:12/2/2008)...rion Health announces that the SouthEast Alaska Re...a, has selected the Rhapsody™ Integration En...d, radiology, pharmacy, laboratory and business pr...to extend connectivity to statewide systems such a...ry) and AKAIMS (an MIS and clinical documentation ...
(Date:12/1/2008)... Including a patient,s ...meticulous reading from the radiologist interpreti...thetic approach, according to a study presented to...ety of North America (RSNA). , , "Our stud...ing and not as an anonymous case study," said lead...
Breaking Medicine News(10 mins):Health News:World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner 2Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 2Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Patient Photos Spur Radiologist Empathy and Eye for Detail 2Health News:Patient Photos Spur Radiologist Empathy and Eye for Detail 3
...ntified particular genes that are most prone to be...alled DNA promoter hypermethylation. Hypermethyla... normal cell development, to generate proteins tha...ehavior, or unregulated cell growth. So far, dat...
... between an extreme form of sleep disorder, REM Be...tia or parkinsonism. Patients with RBD have a hi...tia, Parkinsons disease or multiple system atrophy...pear to stem from a similar neurodegenerative orig...
...iasts and experts in the capital are strongly oppo...ng to recent reports of yet another application fi...l that the very idea of patenting knowledge like y..."Patenting of any kind is highly unjustified and w...
...age for mental illness does not increase usage and...who have children with mental illness, a Yale Scho... Services Research. Prior research has left polic...te parity laws will neither break the bank nor con...
Other Medicine News:Health News:Researchers Have Identified Cancer Promoter Genes 2Health News:Researchers Find Link Between Sleep Disorder and Dementia 2Health News:Yoga Enthusiasts Oppose Patenting Yoga Overseas 2Health News:Coverage for Childrens Mental Illness Reduces Out-of-Pocket Spending 2
Eyeglass Loupe 3x-5x made with precision optical glass. Ideal for any detail work.
Near PT test card/child recog/ playing cards 5 1/2" X 8".
Near point card/newspaper 8 to 48 point type 5 1/2" X 8".
Near point card 4 1/2 to 24 PT 5 1/2" x 8".
Medicine Products: